COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Investigation into the psychosocial and behavioural impact of genetic testing for familial melanoma
Scientific title
Investigation into the psychosocial and behavioural impact of genetic testing for familial melanoma
Secondary ID [1] 300117 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Familial Melanoma 315650 0
Psychosocial Wellbeing 315806 0
Condition category
Condition code
Human Genetics and Inherited Disorders 313939 313939 0 0
Other human genetics and inherited disorders
Cancer 314097 314097 0 0
Malignant melanoma
Mental Health 314098 314098 0 0
Studies of normal psychology, cognitive function and behaviour

Study type
Description of intervention(s) / exposure
The intervention in this study is offering predictive genetic testing for melanoma susceptibility.

Before genetic testing is requested, study participants will attend a pre-testing genetic education and counselling session led by either a genetic counsellor, or a dermatologist trained by a genetic counsellor. During this session participants can ask any questions and will receive education on genetics, the likelihood of detecting a mutation (based on medical/family history), and the possible impact on family members. At the end of this session, participants will decide if they wish to go ahead with genetic testing. For consenting participants, a saliva sample will be collected using a DNA self-collection kit (at the end of the first visit). This sample is sent to an accredited genetic testing laboratory in the USA (Invitae) for panel testing of known genes associated with melanoma risk.

Genetic test results will be reported back to participants during a second (face-to-face) appointment with the genetic counsellor or dermatologist trained by a genetic counsellor. This will be scheduled between 1-3 months after the first visit, depending on when results are available and the availability of staff and participants. This session will include; reporting of results, explanation of significance for personal risk, significance for family risk, recommended preventative health behaviour and screening, and to answer any participant questions.

Intervention code [1] 316391 0
Intervention code [2] 316518 0
Early detection / Screening
Comparator / control treatment
No control group
Control group

Primary outcome [1] 322329 0
The primary outcome of the study is to understand and describe the participant’s experience with living with familial melanoma, and the genetic testing process, with a particular focus on fatalistic beliefs.

This will be achieved by conducting semi-structure interviews with participants, one month after they received their genetic test results. Interviews will be conducted over the phone and should take between 30-60 minutes. The interviews are recorded, and transcribed verbatim. Interview transcripts are then qualitatively analysed using thematic analysis, a process widely used to generate knowledge on the lived experiences of study participants.

Qualitative analysis is commonly used to generate new hypotheses, so there is no 'measurable' primary outcome.

Timepoint [1] 322329 0
1 month after genetic test results are received.
Secondary outcome [1] 378137 0
Pyschosocial Impact of genetic testing, using validated survey instruments and analysed quantitatively.

specific questionnaires used:
- HADS (Hospital Anxiety and Depression Scale) (Zigmond & Snaith 1983)
- Cancer Worry Scale (Custers et al 2014)
- Fatalism Scale (Shen et al 2009)
- Belief in genetic determinism (Carver et al 2017)
- MICRA (Multidimensional Impact of Cancer Risk Assessment) (Cella et al 2002)
- Genomics outcomes scale (Grant et al 2019)
- Genetic Counselling Satisfaction Scale (GCSS) (DeMarco 2004)
- Perceived personal control scale (Berkenstadt et al 1999)
- Decision regret scale (Brehaut et al 2003)
- Decision satisfaction (Holmes-Rovner et al 1996)
- Percieved benefits and limitations of genetic testing (Kasparian et al 2009)
- Multidimensional Health Locus of Control (MHLC) (Wallston et al 1978)
- Health Belief Model (HBM) (Becker & Maiman 1975)
Timepoint [1] 378137 0
1 week, 3 months, 12 months, post genetic test results reported.
Secondary outcome [2] 378138 0
health behaviour change, using self reported information in questionnaires (questionnaire not previously validated, it is specific to this study).

For example; questions on sun exposure and sun protective behaviour (e.g. use of sunscreen, avoiding sun at peak times etc.). Also questions on whether participants have conducted self-skin examinations and attended any clinical skin examinations.
Timepoint [2] 378138 0
3 months and 12 months post genetic test results reported - and compared to baseline self-reported health behaviour.

Key inclusion criteria
- 3 primary melanomas in an individual, and/or
- families with 1 or more invasive melanoma AND 2 or more other invasive melanomas and/or pancreatic cancer among first-degree or second-degree relatives on the same side of the family
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Under 18 years

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
The primary aim is achieved through qualitative methods - using thematic analysis of interview transcripts.

The secondary aims involve questionnaires, which will be analysed quantitatively using subgroup comparisons using paired t-tests and chi-square analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 15526 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 28890 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 304558 0
Name [1] 304558 0
The University of Queensland
Address [1] 304558 0
Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Country [1] 304558 0
Primary sponsor type
The University of Queensland
Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Secondary sponsor category [1] 304839 0
Name [1] 304839 0
Address [1] 304839 0
Country [1] 304839 0

Ethics approval
Ethics application status
Ethics committee name [1] 304984 0
Metro South Health
Ethics committee address [1] 304984 0
37 Kent Street
Woolloongabba QLD 4102
Ethics committee country [1] 304984 0
Date submitted for ethics approval [1] 304984 0
Approval date [1] 304984 0
Ethics approval number [1] 304984 0

Brief summary
Brief description of the study purpose
The study aims to Investigate the psychosocial and behavioural impact of genetic testing for familial melanoma.

Who is it for?
You may be eligible for this study if you are 18 years or older, with 3 primary melanomas and/or a family member with 1 or more invasive melanomas and 2 or more other invasive melanomas and/or pancreatic cancer among first-degree or second-degree relatives on the same side of the family.

Study details
Participation in the study will involve a pre-testing genetic counselling and education visit. Participants will then have their saliva collected for genetic testing, and will attend a second visit to receive their test results. At both visits, participants will be asked to complete questionnaires (approx 30 mins)/ One month after receiving their genetic test results, participants will be asked to complete a phone interview where questions about their experience in the study will be discussed. Participants will also be required to answer questionnaires about the psychological impact of genetic testing and regarding their sun protective behaviour after results have been received. A link to the questionnaires will be emailed to participants at 1 week, 3 months and 12 months after receiving their results, and can be completed online.

It is hoped this study will provide greater insight into the role of genetic testing and the impact on mental health, and sun protective behaviour.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 98862 0
Dr Aideen McInerney-Leo
Address 98862 0
Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Country 98862 0
Phone 98862 0
+61 7 3443 7057
Fax 98862 0
Email 98862 0
Contact person for public queries
Name 98863 0
Mrs Clare Primiero
Address 98863 0
Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Country 98863 0
Phone 98863 0
+61 7 3443 7496
Fax 98863 0
Email 98863 0
Contact person for scientific queries
Name 98864 0
Mrs Clare Primiero
Address 98864 0
Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Country 98864 0
Phone 98864 0
+61 7 3443 7496
Fax 98864 0
Email 98864 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
For now we are unsure what IPD we will produce that may be useful and able to share. We will update this at a later time.
What supporting documents are/will be available?
No other documents available
Summary results
No Results